Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,296
  • Shares Outstanding, K 68,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.59
Trade CRDL with:

Options Overview Details

View History
  • Implied Volatility 157.37% ( +0.10%)
  • Historical Volatility 95.58%
  • IV Percentile 7%
  • IV Rank 5.53%
  • IV High 1,365.74% on 07/13/23
  • IV Low 86.59% on 10/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 174
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 6,145
  • Open Int (30-Day) 5,168

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4300 +16.78%
on 03/25/24
2.0700 -19.32%
on 04/04/24
+0.1700 (+11.33%)
since 03/18/24
3-Month
0.9595 +74.05%
on 02/12/24
2.1700 -23.04%
on 03/01/24
+0.6100 (+57.55%)
since 01/18/24
52-Week
0.5126 +225.79%
on 04/19/23
2.1700 -23.04%
on 03/01/24
+1.1548 (+224.15%)
since 04/18/23

Most Recent Stories

More News
How a Recent M&A Deal Could Catapult a Small-Cap Biotech to New Heights

Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRxâ„¢, is being tested...

NVO : 122.75 (-1.43%)
CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRxâ„¢ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRxâ„¢ granted U.S. FDA Orphan...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024)...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 1.6700 (-4.57%)
CRDL.TO : 2.34 (-3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.8100
2nd Resistance Point 1.7800
1st Resistance Point 1.7250
Last Price 1.6700
1st Support Level 1.6400
2nd Support Level 1.6100
3rd Support Level 1.5550

See More

52-Week High 2.1700
Last Price 1.6700
Fibonacci 61.8% 1.5369
Fibonacci 50% 1.3413
Fibonacci 38.2% 1.1457
52-Week Low 0.5126

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar